Expected to be Effective as of Commencement of Trading on August 15, 2025

ReShape Lifesciences has announced that its shareholders have approved all the necessary proposals to complete the previously announced merger with Vyome Therapeutics. The transaction is expected to take effect at the beginning of trading on Friday, August 15, 2025. Upon completion, the merged company will trade on the Nasdaq Capital Market under the name Vyome Holdings, Inc., with the ticker symbol “HIND.”

Health Technology Insights: OMass Therapeutics Appoints Carol Schafer as Audit Chair

Krishna Gupta, Chairman of Vyome, spoke about the broader vision and goals behind the merger. “Vyome has a wide vision with several promising assets, and we’re focused on building a healthcare platform that spans the US-India innovation corridor,” he said. “We’re excited to trade as a public company under the meaningful ticker symbol ‘HIND,’ which we expect to coincide with India’s Independence Day on August 15. We have a strong and experienced board and management team, and we’re deeply committed to creating value for our new and existing shareholders.”

Health Technology Insights: BioXcel Publishes Study on Dexmedetomidine and Stress Behaviors

Paul Hickey, Chief Executive Officer of ReShape Lifesciences, also expressed appreciation for shareholder support and optimism about the future of the merged entity. “We’re thankful for the strong backing from our shareholders for this merger with Vyome and the sale of our assets to Biorad Medisys. Vyome is well-positioned for success, and we believe this transaction presents a great opportunity for our shareholders as Vyome grows as a Nasdaq-listed public company,” said Hickey.

To support the execution of the transaction, ReShape has retained Maxim Group LLC as its financial advisor, while legal services are being provided by Fox Rothschild LLP. Vyome has appointed Chardan as its financial advisor and Sichenzia Ross Ference Carmel LLP as legal counsel for the deal.

Health Technology Insights: Facephi Unveils AI Defense Tool Against Deepfakes, Attacks

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com